Increased serum amyloid A as potential diagnostic marker for lung cancer: a meta-analysis based on nine studies

Biaoxue, Rong; Liu, Hua; Gao, Wenlong; Yang, Shuanying

doi:10.1186/s12885-016-2882-0

Cited by 42 publications

(36 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sung et al measured 180 healthy and 170 lung adenocarcinoma plasma or serum samples and found a 14-fold increase of SAA levels in the LC patient [45]. Another by Biaoxue, R. et al indicated that SAA alone could detect LC with 0.59 sensitivity and 0.92 specificity [39]. We measured a six-fold increase in SAA levels at all stages of NSCLC compared to healthy controls.…”

Section: Discussionmentioning

confidence: 49%

“…Many of the markers in our set have been studied for decades and have been shown to have potential for diagnosing LC [35][36][37][38][39]. In our studies, certain biomarkers were elevated at higher levels or depressed depending on whether we were looking at early stage (I-II) or late stage (III-IV) NSCLC patients, e.g., the upregulation of CEA and CYFRA-21-1 (common cancer markers widely studied) [36] were not as prominent in early stage NSCLC.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Blood test shows high accuracy in detecting stage I non-small cell lung cancer

Goebel¹,

Louden²,

McKenna³

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

Background: In a previous study (Goebel et. al, Cancer Genomics Proteomics 16:229-244, 2019), we identified 33 biomarkers for an early stage (I-II) Non-Small Cell Lung Cancer (NSCLC) test with 90% accuracy, 80.3% sensitivity, and 95.4% specificity. For the current study, we used a narrowed ensemble of 21 biomarkers while retaining similar accuracy in detecting early stage lung cancer. Methods: A multiplex platform, 486 human plasma samples, and 21 biomarkers were used to develop and validate our algorithm which detects early stage NSCLC. The training set consisted of 258 human plasma with 79 Stage I-II NSCLC samples. The 21 biomarkers with the statistical model (Lung Cancer Detector Test 1, LCDT1) was then validated using 228 novel samples which included 55 Stage I NSCLC. Results: The LCDT1 exhibited 95.6% accuracy, 89.1% sensitivity, and 97.7% specificity in detecting Stage I NSCLC on the blind set. When only NSCLC cancers were analyzed, the specificity increased to 99.1%.Conclusions: Compared to current approved clinical methods for diagnosing NSCLC, the LCDT1 greatly improves accuracy while being non-invasive; a simple, cost-effective, early diagnostic blood test should result in expanding access and increase survival rate.

show abstract

Section: Discussionmentioning

confidence: 49%

Section: Discussionmentioning

confidence: 99%

Blood test shows high accuracy in detecting stage I non-small cell lung cancer

Goebel¹,

Louden²,

McKenna³

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…In a meta-analysis, reports from East Asia, Europe and America have shown SAA as a potential diagnostic biomarker for lung cancer having higher specificity for discerning lung cancer but not appropriate for screening because of lesser sensitivity. 17 Results of the present study reveal that SAA levels can be used as a noninvasive biomarker for screening of lung cancer. Our results are at variance from the findings of the metaanalysis that had suggested a better role in distinguishing lung cancer but not for screening in view of a high specificity but lower sensitivity.…”

Section: 16mentioning

confidence: 54%

Evaluation of serum amyloid A, soluble E-selectin and soluble E-cadherin as lung cancer biomarkers

et al. 2017

View full text Add to dashboard Cite

INTRODUCTIONLung cancer has remained one of the commonest cancers and is the most important cause of cancer related deaths. 1 Symptoms in patients of lung cancer are non-specific and include persistent cough, haemoptysis, shortness of breath, chest pain and debility, which are also seen in many other non-malignant lung diseases. Commonly used investigations for the diagnosis of lung cancer are CT FNAC and bronchoscopy both being interventional. Despite the development of new treatment and therapies designed to increase the 5 year survival rate, lung cancer still remains the deadliest cancer.2 Screening with low dose computed tomography (LDCT) has been advocated but detection of false positive cases with it has been found to be upto 50%, as it also detects non-calcified ABSTRACT Background: Lung cancer screening is a challenge. Sputum cytology, chest X-ray, low dose computed tomography and other screening methods have not proved to be very effective. Serum biomarkers are a new hope in screening of lung cancer. The present study was planned to evaluate sensitivity and specificity of serum levels of amyloid A (SAA), soluble E-selectin (sE-selectin) and soluble E-cadherin (sE-cadherin) as lung cancer biomarkers. Methods: An observational and cross-sectional study comprised of three groups with 20 subjects each of proven lung cancer cases, patients with non-malignant respiratory diseases and healthy controls. Levels of SAA, sE-selectin and sE-cadherin were measured by solid phase sandwich ELISA. Individual and collective sensitivity and specificity of these biomarkers was analysed and cut off values calculated by receiver operating curves. Results: A statistically significant difference was found in the median levels (ng/ml) of SAA in patients of lung cancer, other non-malignant respiratory diseases, and healthy controls, the levels (Mean±SD) being 24980.50±6564.14,9961.10±2000.24 and 580.95±334.94 respectively in the three groups. A sensitivity of 80% and specificity of 55% was found when SAA levels of 1068 ng/ml were taken as cut off for screening of lung cancer. However, no significant difference was found in the serum levels of sE selectin and sE cadherin between the three groups. Moreover, significant association of biomarkers could also not be established with lung cancer when they were used in combination. Conclusions: In this preliminary report from India, SAA has been found to be a promising biomarker in screening for lung cancer.

show abstract

“…At present, earlystage NSCLC is treated by surgical intervention, while mid-late NSCLC is treated with radiotherapy and chemotherapy. Although effective for some patients in the short run, radiotherapy and chemotherapy are associated with adverse effects, toxicity, high recurrence of tumor and poor prognosis [2]. Therefore, it is necessary to reduce the side effects of chemotherapeutic drugs by searching for more effective anticancer drugs with lower toxicity.…”

Section: Introductionmentioning

confidence: 99%